Background: Ovarian cancer was the seventh most frequent cancer worldwide, with 238.700 new cases in 2012, and eight ranked leading cause of cancer mortality, with 151.900 deaths. Most ovarian cancer patients are diagnosed at an advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis. Therefore, the development of a novel biological marker for the diagnosis and prognosis prediction of epithelial ovarian cancer remains urgent. Current literature shows that microRNA-21 (miRNA-21/miR-21), as an oncogenic miRNA, is involved in the growth, metastasis and apoptosis of cancer cells through its control of various target molecules and signaling pathways
Objective: To determine the differences expression of miR-21 in blood plasma epithelial ovarian cancer patient (EOC) between early stage epithelial ovarian cancer and advanced stage.
Methods: This study is a cross sectional study in 40 epithelial ovarian cancer patients that underwent primary surgery for suspected ovarian cancer. Blood sample taken prior to surgery and when pathological anatomy result confirmed it is an epithelial ovarian cancer, then the RNA was isolated. Based on the RNA, the cDNA was synthesized and run through qPCR. All the data will be analyses with GenEx analyzing software.
Results: The expression of miR-21 in advanced stage EOC is 1,36 fold compare to early stage (p=0,52), expression of miR-21 in type II EOC is 1,33 fold compare to type I EOC (p=0,56), and expression of miR-21 in residual tumor >1cm after surgery is 1,30 fold compare to residual tumor after surgery < 1cm (p=0,59)
Conclusion:. Despite a trend, there was no significant increase in the expression of circulating miRâ€21 in severity of stages, histopathology type and residual tumor in this study. In conclusion, the circulating miR-21 may be promising candidate biomarkers for EOC that require validation in a larger study.